Cancer Survivorship Training Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

BETHESDA, Md-In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

BETHESDA, Md—In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

The training program was developed by NCI’s Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.

To obtain a free copy of the training program, please contact the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Related Content
Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Tim Cortese
April 25th 2025
Article

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Russ Conroy
April 25th 2025
Article

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.